Medicine logistics in emerging markets: Southeast Asia
We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.
As growth in developed markets stagnates somewhat, many in the pharmaceutical industry aspire to access the populations in need of better medicine access within emerging markets.
Emerging markets are defined as countries developing in prosperity and likely to achieve higher income. Around 70% of the world’s population live within these markets.
Many of these regions express a strong demand for better access to medicines and health solutions with millions of vaccine preventable deaths being caused due to inadequate supply.
Medicines in southeast Asia
Southeast Asia is experiencing a rise in its number of clinical trials. The lower running cost for clinical trials are attractive to drug manufacturers as they seek to reduce R&D costs. Deloitte expects this factor to only drive the region’s level of clinical trials.
ASEAN (The Association of Southeast Asian Nations) countries are indeed increasing in significance, however these regions do boast varying levels of infrastructure, medical spend and process development.
Download this infographic to explore the key elements impacting pharmaceutical supply chains running through southeast Asia.
Stay tuned for parts two and three of this infographic series looking at Africa and Latin America.
TO READ THE FULL STORY
Please note: That all fields marked with an asterisk (*) are required.